Treatment Updates for Neuromuscular Channelopathies.

ABSTRACT:

Purpose of review

This article aims to review the current and upcoming treatment options of primary muscle channelopathies including the non-dystrophic myotonias and periodic paralyses.

Recent findings

The efficacy of mexiletine in the treatment of myotonia is now supported by two randomised placebo-controlled trials, one of which utilised a novel aggregated n-of-1 design. This has resulted in licencing of the drug via orphan drug status. There is also good evidence that mexiletine is well tolerated and safe in this patient group without the need for intensive monitoring. A range of alternative antimyotonic treatment options include lamotrigine, carbamazepine and ranolazine exist with variable evidence base. In vitro studies have shown insight into reasons for treatment fail

SUBMITTER: Jitpimolmard N 

PROVIDER: S-EPMC7443183 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature